Incyte
INCY
#1208
Rank
โ‚ฌ16.33 B
Marketcap
81,77ย โ‚ฌ
Share price
-0.13%
Change (1 day)
43.95%
Change (1 year)

Revenue for Incyte (INCY)

Revenue in 2026 (TTM): โ‚ฌ4.57 Billion

According to Incyte's latest financial reports the company's current revenue (TTM ) is โ‚ฌ4.60 Billion. In 2025 the company made a revenue of โ‚ฌ4.37 Billion an increase over the revenue in the year 2024 that were of โ‚ฌ4.07 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Incyte from 1996 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚ฌ4.57 B4.59%
2025 โ‚ฌ4.37 B7.38%
2024 โ‚ฌ4.07 B21.91%
2023 โ‚ฌ3.34 B5.64%
2022 โ‚ฌ3.16 B20.02%
2021 โ‚ฌ2.63 B21.62%
2020 โ‚ฌ2.16 B12.51%
2019 โ‚ฌ1.92 B17.15%
2018 โ‚ฌ1.64 B28.48%
2017 โ‚ฌ1.28 B21.8%
2016 โ‚ฌ1.05 B52.49%
2015 โ‚ฌ0.68 B63.91%
2014 โ‚ฌ0.42 B63.63%
2013 โ‚ฌ0.25 B14.45%
2012 โ‚ฌ0.22 B208.76%
2011 โ‚ฌ72.73 M-43.05%
2010 โ‚ฌ0.12 B1874.94%
2009 โ‚ฌ6.46 M130.63%
2008 โ‚ฌ2.8 M-88.11%
2007 โ‚ฌ23.58 M12.59%
2006 โ‚ฌ20.95 M216.27%
2005 โ‚ฌ6.62 M-16.56%
2004 โ‚ฌ7.93 M-78.78%
2003 โ‚ฌ37.4 M-61.52%
2002 โ‚ฌ97.2 M-60.85%
2001 โ‚ฌ0.24 B20.46%
2000 โ‚ฌ0.20 B32.07%
1999 โ‚ฌ0.15 B37.39%
1998 โ‚ฌ0.11 B51.12%
1997 โ‚ฌ75.16 M117.03%
1996 โ‚ฌ34.63 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novartis
NVS
โ‚ฌ48.60 B 955.36%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
โ‚ฌ54.38 B 1,081.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚ฌ62.06 B 1,247.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ31.97 B 594.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Ligand Pharmaceuticals
LGND
โ‚ฌ0.23 B-95.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
โ‚ฌ0.15 B-96.57%๐Ÿ‡บ๐Ÿ‡ธ USA
CTI BioPharma
CTIC
โ‚ฌ65.08 M-98.59%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚ฌ81.02 M-98.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Ardelyx
ARDX
โ‚ฌ0.36 B-92.02%๐Ÿ‡บ๐Ÿ‡ธ USA